A step in the right direction, but one size might not fit all

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 930-931

  Noble, Simon ^a  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBRINOPEPTIDE A; NADROPARIN; PLACEBO; PROTEIN C; THROMBIN;

BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOPENIA; HUMAN; INFECTION; LETTER; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOGENICITY; THROMBOSIS PREVENTION;

ANTINEOPLASTIC AGENTS; FIBRINOLYTIC AGENTS; HUMANS; LUNG NEOPLASMS; NADROPARIN; PANCREATIC NEOPLASMS; THROMBOEMBOLISM;

EID: 70349405885     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70293-1     Document Type: Letter

References (5)

1. Agnelli G., Gussoni G., Bianchini C., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10 (2009) 943-949
2. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., and Lyman G.H. Frequency, risk factors and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110 (2007) 2339-2346
3. Khorana A.K., Kunderer N.M., Culakova E., et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 (2008) 4902-4907
4. Haddad T.C., and Greeno E.W. Chemotherapy-induced thrombosis. Thromb Res 118 (2006) 555-568
5. Maraveyas A., Holmes M., Lofts F., Garadi K.K., Gardiner E., and Sgouros J. Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): results of the interim analysis of the FRAGEM trial. Proc Am Soc Clin Oncol 25 suppl 18S (2007) 4583